Amgen reports data for anti-PCSK9 mAb

Amgen Inc. (NASDAQ:AMGN) said subcutaneous AMG 145 given every two weeks in a Phase Ib hypercholesterolemia trial reduced mean LDL-C by up to 75% vs. placebo at week six in patients on low to moderate...